Medpace Holdings ($MEDP) has risen 1,603% since December 2016, while earnings increased 1,017%; the post cites a 35.69x blended P/E and no dividend. The analysis says growth is slowing and the current valuation depends on investors continuing to pay about 34x earnings for roughly 11% forward growth; at 15x earnings, it estimates a 2028 share price of $323, nearly 50% below the price at the time of the post.